Overview

Pleco has set out to develop a safe and efficient product that is designed to detoxify the cancer-promoting micro-environment. This novel treatment is deployed to boost existing therapies and its effect is achieved through a carefully optimised combination of chemical compounds. Thus Pleco introduces a novel category of cancer medicines with a First-in-Class product that addresses the root of cancer, not just the tumour itself.
 
The first treatments are aimed at Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.

Executive Team

Ivo Timmermans MD MBA
Chief Executive Officer

View bio

Rudi Jansen
Chief Business Officer

View bio

Dan Gelvan PhD
Chief R&D Officer

View bio

Gerben de Rijk LLM
Chief Legal Officer

View bio

Non-Executive Team

Gerard van Leijenhorst

Gerard van Leijenhorst MD
Non-Executive Director

View bio

Debra Ainge PhD MIOD
Non-Executive Director

View bio
Callum Meikle

Callum Meikle
Non-Executive Director

View bio

Brenda Reynolds
Non-Executive Director

View bio

Pictures: Bas Beekhuizen

Executive Team

Ivo Timmermans MD MBA
Chief Executive Officer

View bio

Rudi Jansen
Chief Business Officer

View bio

Dan Gelvan PhD
Chief Scientific Officer

View bio

Gerben de Rijk LLM
Chief Legal Officer

View bio

Non-Executive Team

Gerard van Leijenhorst

Gerard van Leijenhorst MD
Non-Executive Director

View bio

Debra Ainge PhD MIOD
Non-Executive Director

View bio
Callum Meikle

Callum Meikle
Non-Executive Director

View bio

Brenda Reynolds
Non-Executive Director

View bio

Pictures: Bas Beekhuizen